Scientific Advisors

Nicholas Barnes, Ph.D., 5-HT3 Principal Advisor

Dr. Barnes has extensive expertise with the pharmacology of the neurotransmitter serotonin (5-HT), particularly with the 5-HT3 receptor, and is the Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for Serotonin Receptors. He is the principal founder and CEO of Celentyx Ltd, a venture capital financed pharmaceutical R&D company focusing on diseases of the immune system, and has a proven track record in the investigation of drug targets and the delivery of development compounds. He is also a Fellow of the British Pharmacological Society and an Honorary Professor at a number of major universities around the globe as well as being Editor-in-Chief, Editor and Associate Editor for the international journals Frontiers in Neuropharmacology, Neuropharmacology, and Frontiers in Neuroscience, respectively.

H. James Harwood, Ph.D., Advisor

Dr. Harwood is a former Principal Research Investigator at Pfizer. Currently, he is the Founder and Chief Consultant at Delphi BioMedical Consultants LLC, Adjunct Professor Department of Cell and Molecular Biology and Health Professions Advisory Committee Member at the University of Rhode Island, and Adjunct Professor Department of Pathology at Wake Forest University. Jim brings more than 30-year experience in drug R&D in pharmaceutical industry especially in physiology and pharmacology of metabolic and cardiovascular diseases.

Nick Moore, Ph.D., Advisor

Dr. Moore has over 30-year experience in the discovery & development from early compound identification to clinical Proof of Concept (PoC). He was an original member of the team that discovered olanzapine (Zyprexa®). In 1999, he received the prestigious ‘Society for Medicines Research Award for Drug Discovery’ for his contributions to the discovery and development of Zyprexa®. In 2005, Nick joined Lundbeck Research USA as the Associate Director of Neuroscience with responsibility for the pre-clinical development of Lundbeck’s late stage antidepressant, vortioxetine (Trintellix®). Nick was the Director of Development and Pharmacology at Albany Molecular Research Inc. (AMRI) with responsibility for overseeing AMRI’s late-stage internal drug discovery programs including the clinical trial of CSTI-100 (ALB-127158).